sibeprenlimab

Home
Ligands
sibeprenlimab

GtoPdb Ligand ID: 12102

Synonyms: VIS-649 | VIS649

Comment: Sibeprenlimab (VIS-649) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13) [1,4]. The antibody binds with high affinity to human trimeric APRIL, and potently blocks APRIL binding to its receptors TACI (transmembrane activator and CAML interactor) and BCMA (B-cell maturation antigen). It was developed by Visterra for anti-inflammatory potential.

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
APRIL is predicted to promote B cell class switching to IgA production via signalling through the Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Elevated APRIL levels are associated with the pathology of IgA nephropathy. Hence, mAb-mediated neutralisation of APRIL to reduce TACI activation is a promising mechanism for the treament of IgA nephropathy.

Immunopharmacology Comments

APRIL is predicted to promote B cell class switching to IgA production via signalling through the Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Elevated APRIL levels are associated with the pathology of IgA nephropathy. Hence, mAb-mediated neutralisation of APRIL to reduce TACI activation is a promising mechanism for the treament of IgA nephropathy.